gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · ANROHealthcarePharmaceuticals

Alto Neuroscience Inc. (ANRO)

$22.19−1.81%
Close Nov 2, 2026 · split-adjusted
Oct 30, 2026$22.60▲ 85.70% in range
Nov 3, 2025Low $11.13 · High $36.64Oct 30, 2026
What changed · written from our data
As of Nov 2, 2026

Alto Neuroscience closed at $22.19 on Nov 2, down 1.81%, 39.4% below its 52-week closing high. Volume of 473.3K shares was 0.77× its 20-day average (below normal).

Split-adjusted performance: -10.5% over one month, -11.9% over six months, +55.0% over one year.

Short interest was 5.2M shares at the Oct 15 settlement, up 11.7% from the prior report (20.0% of float, 7.5 days to cover).

Market cap$870.8M39.2M shares
Revenue · quarter$0.00—
Diluted EPS$-0.65—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range11.13 – 36.64−39.4% from high
Volume473.3K0.77× 20-day avg
Volatility · 60d56.1%Annualised
Short % of float20.0%7.5 days to cover
Net cash$225.1MCash $243.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.4%1M −10.5%3M −21.4%6M −11.9%YTD +24.7%1Y +55.0%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum63
Revenue growth—
Net margin—
Value (low P/E)—
Size69

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →
Shares short5.2M+11.7% vs prior
Days to cover7.5Settled Oct 15
% of float20.0%
Short vol. 10d66.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ANROAlto Neuroscience$22.19−1.81%−11.9%———$870.8M
KURAKura Oncology$9.79−4.58%+5.8%+36.5%−327.3%—$870.9MCompare
JBIOJade Biosciences$13.93−0.92%−43.2%———$885.9MCompare
OBXObsidian Therapeutics$14.43−2.43%————$891.4MCompare
LTGOLatigo Biotherapeutics$13.51−3.15%————$895.7MCompare
ALMSAlumis$6.38−5.20%−74.7%−37.7%−8557.2%—$825.8MCompare
CYRXCryoPort$16.23−6.13%+59.0%+7.7%−20.9%—$822.0MCompare
CRVSCorvus Pharmaceuticals$9.70−3.29%−39.5%———$816.0MCompare
AKTSAktis Oncology$14.59−8.41%−23.2%—−713.5%—$811.5MCompare

News about Alto Neuroscience

All news →
Here's Why You Should Add ANRO Stock to Your Portfolio NowZacks Investment Research · Oct 14, 2026▲ Positive

Quick answers

What does Alto Neuroscience do?
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
What is ANRO's market cap?
$870.78M, based on the Nov 2 close of $22.19.
Does Alto Neuroscience pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ANRO is sold short?
5.2M shares, 20.0% of float, as of Oct 15, 2026.
What sector is ANRO in?
Healthcare, in the Pharmaceuticals industry.

About Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

HQ: Mountain View, CA68 employeesListed Feb 2, 2024altoneuroscience.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology